India's pharmaceutical industry is seeking a one-time exemption from price control measures tied to the declining wholesale price index (WPI). Under the Drug Price Control Order (DPCO) 2013, scheduled drug prices are revised based on the previous year's WPI. Industry executives argue that this would lead to marginal reductions and are requesting an exemption due to rising input costs, aiming to make a representation to India's drug pricing authority. Last year saw a record 12% increase in essential medicine prices linked to the WPI.
